bibliographic resource 334709 [br/334709]
https://w3id.org/oc/corpus/br/334709
- is a
-
- title
-
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- subtitle
-
- Bortezomib with or without Siltuximab in Multiple Myeloma
- publication date
-
- contributor
-
- format
-
- identifier
-
- part of
-